Histone deacetylase inhibitors - Turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases

Applied Microbiology and Biotechnology

Volumn 75, Issue 3, 2007, Pages 499-514

  Riester, Daniel ^a   Hildmann, Christian ^a   Schwienhorst, Andreas ^a  

^a Institute for Microbiology and Genetics   (Germany)

Author keywords

Benzamides; Cancer drug design; Clinical trials; Epigenetics; Histone deacetylase inhibitors; Hydroxamates

Indexed keywords

BENZAMIDES; CANCER DRUG DESIGN; CLINICAL TRIALS; EPIGENETICS; HISTONE DEACETYLASE INHIBITORS; HYDROXAMATES;

CELLS; CHEMOTHERAPY; DRUG PRODUCTS; MEDICAL PROBLEMS; PATIENT MONITORING; TUMORS;

ENZYME INHIBITION;

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; ARYLBUTYRIC ACID DERIVATIVE; AVUGANE; BACECA; CRA 024781; CRA 026440; CYCLIN DEPENDENT KINASE INHIBITOR; DNA VACCINE; FR 901228; G2M 777; HDAC 42; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; ITF 2357; LBH 589; MGCD 0103; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PDX 101; PHENYLACETIC ACID; PIVALOYLOXYMETHYL BUTYRATE; PYROXAMIDE; RETINOIC ACID; SAVICOL; TRAPOXIN A; TRIBUTYRIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; US 6034096; VALPROATE SEMISODIUM; VALPROIC ACID; VORINOSTAT; VX 563; WO 9743251;

CANCER; DISEASE TREATMENT; DRUG DEVELOPMENT; GENE EXPRESSION; GENETICS; INHIBITOR; PROTEIN; TUMOR;

ACNE VULGARIS; AMYOTROPHIC LATERAL SCLEROSIS; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BASAL CELL CARCINOMA; CANCER INHIBITION; CANCER THERAPY; CARDIOTOXICITY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CLINICAL TRIAL; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DRUG INDICATION; DRUG WITHDRAWAL; ENZYME INHIBITION; EXPERIMENTAL MOUSE; GENE REPRESSION; GENETIC EPIGENESIS; GENETIC REGULATION; HEMATOLOGIC MALIGNANCY; HEREDITARY SPINAL MUSCULAR ATROPHY; HIGH THROUGHPUT SCREENING; HUMAN; INFLAMMATORY DISEASE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOGENESIS; SHORT SURVEY; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS;

EID: 34248644319     PISSN: 01757598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00253-007-0912-1     Document Type: Short Survey

References (204)

1. Acharya MR, Sparreboom A, Venitz J, Figg WD (2005) Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 68:917-932
2. Adcock IM (2006) Histone deacetylase inhibitors as novel anti-inflammatory agents. Curr Opin Investig Drugs 7:966-973
3. Alarcon JM, Malleret G, Touzani K, Vronskaya S, Ishii S, Kandel ER, Barco A (2004) Chromatin acetylation, memory, and LTP are impaired in CBP+/-mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 42:947-959
4. Anandan S-K, Ward JS, Brokx RD, Bray MR, Patel DV, Xiao X-X (2005) Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem 15:1969-1972
5. Antos CL, McKinsey TA, Dreitz M, Hollingsworth LM, Zhang C-L, Schreiber K, Rindt H, Gorczynski RJ, Olson EN (2003) Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem 278:28930-28937
6. Archer SY, Meng S, Shei A, Hodin RA (1998) p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 95:6791-6796
7. Archer SY, Tang R, Kim H-J, Hodin RA (2001) A novel butyrate prodrug induces differentiation and the program of cell cycle inhibition in colon cancer cells. Surg Forum 52:254-255
8. Armeanu S, Pathil A, Venturelli S, Mascagni P, Weiss TS, Gottlicher M, Gregor M, Lauer UM, Bitzer M (2005) Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol 42:210-217
9. Atadja P, Hsu M, Kwon P, Trogani N, Bhalla K, Remiszewski SW (2004) Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824. Novartis Found Symp 259:249-266
10. Bali P, George P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Scuto A, Annavarapu S, Fiskus W, Moscinski L, Atadja P, Bhalla K (2004) Superior activity of the combination of histone deacetylase inhibitor LAQ824 and FLT-3 kinase inhibitor PPKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res 10:4991-4997
11. Bar-Ner M, Thibault A, Tsokos M, Magrath IT, Samid D (1999) Phenylbutyrate induces cell differentiation and modulates Epstein-Barr virus expression in Burkitt's lymphoma cells. Clin Cancer Res 5:1509-1516
12. Beglopoulos V, Shen J (2006) Regulation of CRE-dependent transcription by presenilins: prospects for therapy of Alzheimer's disease. Trends Pharmacol Sci 27:33-40
13. Berger MR, Bischoff H, Fritschi E, Henne T, Herrmann M, Pool BL, Satzinger G, Schmahl D, Weiershausen U (1985) Synthesis, toxicity and therapeutic efficacy of 4-amino-N-(2′-aminophenyl) benzamide: a new compound preferentially active in slowly growing tumors. Cancer Treat Rep 69:1415-1424
14. Bhuiyan MPI, Kato T, Okauchi T, Nishino N, Maeda S, Nishino TG, Yoshida M (2006) Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylase. Bioorg Med Chem 14:3438-3446
15. Bi G, Jiang G (2006) The molecular mechanism of HDAC inhibitors in anticancer effects. Cell Mol Immunol 3:285-290
16. Bieler A, Mantwill K, Dravits T, Bernshausen A, Glockzin G, Kohler-Vargas N, Lage H, Gansbacher B, Holm PS (2006) Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus d1520. Hum Gene Ther 17:55-70
17. Blanchard F, Chipoy C (2005) Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today 10:197-204
18. Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romanski A, Kramer OH, Kampfmann M, Hoelzer D, Neubauer A, Ruthardt M, Ottmann OG (2005) Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 104:2717-2725
19. Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L, Schultz BE, Young PR, Dalrymple SA (2006) CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther 5:1309-1317
20. Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, LaQuaglica MP, Drobnjak M, Cordon-Cardo C, Scher HI, Beslow R, Richon VM, Rifkind RA, Marks PA (2001) Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res 7:962-970
21. Butler LM, Zhoudagger X, Xu W-S, Scher H I, Rifkind RA, Marks PA, Richondagger VM (2002) The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99:11700-11705
22. Butler LM, Liapis V, Bouralexis S, Welldon K, Hay S, Thai le M, Labrinidis A, Tilley WD, Findlay DM, Evdokiou A (2006) The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int J Cancer 119:944-954
23. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Sklenar AR, Davis ME, Lucas DM, Fischer B, Shank R, Tejaswi SL, Binkley P, Wright J, Chan KK, Grever MR (2005) A phase I and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105:959-967
24. Cao ZA, Bass KE, Balasubramanian S, Liu L, Schultz B, Verner E, Dai Y, Molina RA, Davis JR, Misialek S, Sendzik M, Orr CJ, Leung L, Callan O, Young P, Dalrymple SA, Buggy JJ (2006) CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo. Mol Cancer Ther 5:1693-1701
25. Catley L, Weisberg E, Kiziltepe T, Tai Y-T, Hideshima TPN, Tassone P, Atadja P, Chauhan D, Munshi NC, Anderson K C (2006) Aggresome induction by proteasome inhibitor bortezomib and a-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 108:3441-3449
26. Celera (2005) http://www.redorbit.com/modules/news/tools.php?tool= print&id=172745
27. Chen J, Bai H, Wang C, Kang J (2006) Trichostatin A improves the anticancer activity of low concentrations of curcumin in human leukemia cells. Pharmazie 61:710-716
28. Chinnaiyan P, Allen GW, Harari PM (2006) Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-IR, PI3K, and Ras. Semin Radiat Oncol 16:59-64
29. Choi JH, Oh SW, Kang MS, Kwon HJ, Oh GT, Kim D-Y (2005) Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy 35:89-96
30. Chung D (2002) Histone modification: the "next wave" in cancer therapeutics. Trends Mol Med 8:S10-S11
31. Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, Nanni M, Careddu A, Fazi F, Padula F, Fiorini R, Spiriti MAA, Petti MC, Venditti A, Amadori S, Mandelli F, Pelicci PG, Nervi C (2006) Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 66:8903-8911
32. Cohen LA, Marks PA, Rifkind RA, Amin S, Desai D, Pittman B, Richon VM (2002) Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. Anticancer Res 22:1497-1504
33. Conley BA, Egorin MJ, Tait N, Rosen DM, Sausville EA, Dover G, Fram RJ, Van Echo DA (1998) Phase I study of the orally administered butyrate prodrug tributyrin, in patients with solid tumors. Clin Cancer Res 4:629-634
34. Coradini D, Zorzet S, Rossin R, Scarlata I, Pellizzaro C, Turrin C, Bello M, Cantoni S, Speranza A, Sava G, Mazzi U, Perbellini A (2004) Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin Cancer Res 10:4822-4830
35. Dashmahapatra G, Almenara JA, Grant S (2006) Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cell that overexpress Bcl-2. Mol Pharmacol 69:288-298
36. De Ruijter AJ, Leen R, Hoebink J, Caron HN, van Kuilenburg AB (2006) Antagonist effects of sequential administration of BL1521, a histone deacetylase inhibitor, and gemcitabine to neuroblastoma cells. Cancer Lett 233:240-246
37. Drummond DC, Marx C, Guo Z, Scott G, Noble C, Wang D, Pallavicini M, Kirpotin DB, Benz CC (2005a) Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes. Clin Cancer Res 11:3392-3401
38. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC (2005b) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45:495-528
39. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VN, Frankel S (2007) Phase II trial of oral vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31-39
40. Edelman MJ, Bauer K, Khanwani S, Tait N, Trepel J, Karp J, Nemieboka N, Chung E-J, Van Echo D (2003) Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug. Cancer Chemother Pharmocol 51:439-444
41. Elliott P (2006) http://sirtrispharma.hubspot.com/News/PressReleases/ tabid/3693/articleType/ArticleView/articleId/1062/Default.aspx
42. Entin-Meer M, Rephaeli A, Yang X, Nudelman A, VandenBerg SR, Haas-Kogan DA (2005) Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas. Mol Cancer Ther 4:1952-1961
43. Eyüpoglu IY, Hahnen E, Buslei R, Siebzehnrübl FA, Savaskan NE, Lüders M, Tränkle C, Wick W, Weller M, Fahlbusch R, Blümcke I (2005) Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J Neurochem 93:992-999
44. Eyüpoglu IY, Hahnen E, Tränkle C, Savaskan NE, Siebzehnrübl FA, Buslei R, Lemke D, Wick W, Fahlbusch R, Blümcke I (2006) Experimental therapy of malignant glioma using the inhibitor of histone deacetylase MS-275. Mol Cancer Ther 5:1248-1255
45. Farrel R (2004) http://www.titanpharm.com/press/Pivanex-Melanoma.htm
46. Fenrick R, Hiebert SW (1998) Role of histone deacetylase in acute leukemia. J Cell Biochem 30/31(Suppl):194-202
47. Ferrick R, Hiebert SW (1998) Role of histone deacetylases in acute leukemia. J Cell Biochem 30/31(Suppl):194-202
48. Fiskus W, Prampat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K (2006a) Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imtinib mesylate-sensitive or imtinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res 12:5869-5878
49. Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Boyapalle S, Rocha K, Wu J, Giles F, Manley PW, Atadja P, Bhalla K (2006b) Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 108:645-652
50. Fouladi M, Furman WL, Chin T, Freeman BB III, Dudkin L, Stewart CF, Krailo MD, Speights R, Ingle AM, Houghton PJ, Wright J, Adamson PC, Blaney SM (2006) Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a children's oncology group report. J Clin Oncol 24:3678-3685
51. Frey RR, Wada CK, Garland RB, Curtin ML, Michaelides MR, Li J, Pease LJ, Glaser KB, Marcotte PA, Bouska JJ, Murphy SS, Davidsen SK (2002) Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett 12:3443-3447
52. Garber K (2007) HDAC inhibitors overcome first hurdle. Nat Biotechnol 25:17-19
53. Garcia-Manero G, Yang H, Sanchez-Gonzalez B et al (2005) Final results of a phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with leukemia and myelodysplastic syndrome. Blood 106:123a, (Abstract 408)
54. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'Brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa J-P (2006) Phase I/II study of the combination of 5-aza-2′- deoxycytidine with valproic acid in patients with leukemia. Blood 108:3271-3279
55. Garcia-Morales P, Gómez-Martinez A, Carrato A, Martinez-Lacaci I, Barberá VM, Soto JL, Carrasco-Garcia E, Menéndez-Gutierrez MP, Castro-Galache MD, Ferragut JA, Saceda M (2005) Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. Mol Cancer Ther 4:1222-1230
56. Gartel AL, Tyner AL (1999) Transcriptional regulation of the p21(WAF1/CIP1) gene. Exp Cell Res 246:280-289
57. Gartel AL, Tyner AL (2002) The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1:639-649
58. Gaschott T, Steinhilber D, Milovic V, Stein J (2001) Tributyrin, a stable and rapidly absorbed prodrug of butyric acid, enhances antiproliferative effects of dihydroxycholecalciferol in human colon cancer cells. J Nutr 131:1839-1843
59. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K (2005) Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105:1768-1776
60. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M, Bhalla K (2006) A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematological malignancies. Clin Cancer Res 12:4628-4635
61. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2:151-163
62. Golay J, Cuppini L, Leoni F, Micò C, Domenghini M, Lombardi L, Neri A, Barbui AM, Salvi A, Porro G, Pagani P, Fossati G, Mascagni P, Introna M, Rambaldi A (2006) The histone deacetylase inhibitor ITF2357 induces apoptosis of leukemia cells and inhibits IL-6 and VEGF production by bone marrow mesenchymal stromal cells. Haematol Rep 2:16
63. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, Grever M, Galm O, Dauses T, Karp JE, Rudek MA, Zhao M, Smith BD, Manning J, Jiemjit A, Dover G, Mays A, Zwiebel J, Murgo A, Weng LJ, Herman JG (2006) Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66:6361-6369
64. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Coco FL, Nervi C, Pelicci PG, Heinzel T (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969-6978
65. Grozinger CM, Schreiber SL (2002) Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol 9:3-16
66. Grunstein M (1997) Histone acetylation in chromatin structure and transcription. Nature 389:349-352
67. Gu W, Nusinzon I, Smith RD, Horvarth CM, Silverman RB (2006) Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: potent inhibition of histone deacetylases. Bioorg Med Chem 14:3320-3329
68. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA (2004) Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 101:1241-1246
69. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS (2004) Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64:1079-1086
70. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL (2003) Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 100:4389-4394
71. Hahnen E, Eyupoglu IY, Brichta L, Haastert K, Trankle C, Siebzehnrubl FA, Riessland M, Holker I, Claus P, Romstock J, Buslei R, Wirth B, Blumcke I (2006) In vitro evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J Neurochem 98:193-202
72. Hamamori Y, Schneider MD (2003) HATs off to Hop: recruitment of a class I histone deacetylase incriminates a novel transcriptional pathway that opposes cardiac hypertrophy. J Clin Invest 112:824-826
73. Hanessian S, Vinci V, Auzzas L, Marzi M, Giannini G (2006) Exploring alternative Zn-binding groups in the design of HDAC inhibitors: squaric acid, N-hydroxyurea, and oxazoline analogues of SAHA. Bioorg Med Chem 16:4784-4787
74. Hausschild A, Trefzer U, Garbe C, Kaehler K, Ugurel S, Kiecker F, Eigentler T, Krissel H, Schadendorf D (2006) A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma. J Clin Oncol 24:18S, (8044)
75. Heltweg B, Dequiedt F, Marshall BL, Brauch C, Yoshida M, Nishino N, Verdin E, Jung M (2004) Subtype selective substrates for histone deacetylases. J Med Chem 47:5235-5243
76. Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, Goehle S, Kollipara R, DePinho RA, Gu Y, Simon JA, Bedalov A (2006) Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 66:4368-4377
77. Hildmann C, Wegener D, Riester D, Hempel R, Schober A, Merana J, Giurato L, Guccione S, Nielsen TK, Ficner R, Schwienhorst A (2006) Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases. J Biotechnol 124:258-270
78. Hildmann C, Riester D, Schwienhorst A (2007) Histone deacetylases-an important class of cellular regulators with a variety of functions. Appl Microbiol Biotechnol (in press)
79. Horton TM, Gannavarapu A, Blaney SM, D'Argenio DZ, Plon SE, Berg SL (2006) Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol 58:13-23
80. Hoshijima M, Chien KR (2002) Mixed signals in heart failure: cancer rules. J Clin Invest 109:849-855
81. Hsi LC, Xi X, Lotan R, Shureiqi I, Lippman SM (2004) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Cancer Res 64:8778-8781
82. Huang L (2006) Targeting histone deacetylases for the treatment of cancer and inflammatory diseases. J Cell Physiol 209:611-616
83. Huang L, Pardee AB (2000) Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 6:849-866
84. Huang L, Sowa Y, Sakai T, Pardee AB (2000) Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 19:5712-5719
85. Hurtubise A, Momparler RL (2006) Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2′-deoxycytidine (decitabine) on human breast carcinoma cells. Cancer Chemother Pharmacol 58:618-625
86. Imre G, Gekeler V, Leja A, Beckers T, Boehm M (2006) Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down regulation. Cancer Res 66:5409-5418
87. Insiga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S, Pelicci PG (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11:71-76
88. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ (2002) A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 99:8921-8926
89. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, Barnes PJ (2005) Decreased histone deacetylase activity in chronic obstructive pulmonary disease. New Engl J Med 352:1967-1976
90. Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev 1:287-299
91. Karagiannis TC, El-Osta A (2006) Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene 25:3885-3893
92. Kariya S, Hirano M, Uesato S, Nagai Y, Nagaoka Y, Furiya Y, Asai H, Fujikake N, Toda T, Ueno S (2006) Cytoprotective effect of histone deacetylase inhibitors against polyglutamine toxicity. Neurosci Lett 392:213-215
93. Kee HJ, Sohn IS, Nam KI, Park JE, Yin Z, Ahn Y, Jeong MH, Bang YJ, Kim N, Kim JK, Kim KK, Epstein JA, Kook H (2006) Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 113:51-59
94. Kelly WK, O'Connor OA, Marks PA (2002) Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs 11:1695-1713
95. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9:3578-3588
96. Khan SB, Maududi T, Barton K, Ayers J, Alkan S (2006) Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol 125:156-161
97. Kim YB, Ki SW, Yoshida M, Horinouchi S (2000) Mechanisms of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. J Antibiot 53:1191-1200
98. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, Kim CW, Kim KW (2001) Deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Genet 7:437-443
99. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63:7291-7300
100. Kim IA, Shin JH, Kim IH, Kim JH, Kim JS, Wu HG, Chie EK, Ha SW, Park CI, Kao GD (2006) Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53. Clin Cancer Res 12:940-949
101. Kong Y, Tannous P, Lu G, Berenji K, Rothermel BA, Olson EN, Hill JA (2006) Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 113:2579-2588
102. Kook H, Lepore JJ, Gitler AD, Lu MM, Yung WW-M, Mackay J, Zhou R, Ferrari V, Gruber P, Epstein JA (2002) Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest 112:863-871
103. Kouraklis G, Misiakos EP, Theocharis S (2006) Histone deacetylase inhibitors as a potential therapeutic agent for human cancer treatment. Targeted Oncol 1:34-41
104. Kristeleit RS, Tandy D, Atadja P, Patnaik A, Scott J, De Bono JS, Judson I, Kaye SB, Workman P, Aherne W (2004) Effects of the histone deacetylase inhibitor (HDACI) LAQ824 on histone acetylation, Hsp70 and c-Raf in peripheral blood lymphocytes from patients with advanced solid tumours enrolled in a phase I clinical trial. J Clin Oncol 22:3023
105. Kuefer R, Hofer MD, Altug V, Zorn C, Genze F, Kunzi-Rapp K, Hautmann RE, Gschwend JE (2004) Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer 90:535-541
106. Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, Germing U, Haas R, Dohner H, Gattermann N (2005) The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 106:112-119
107. Kulp SK, Chen C-S, Wang D-S, Chen C-Y, Chen C-S (2006) Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin Cancer Res 12:5199-5206
108. Leoni F, Fossati G, Lewis EC, Lee J-K, Porro G, Pagani P, Modena D, Moras ML, Pozzi P, Reznikov LL, Siegmund B, Fantuzzi G, Dinarello CA, Mascagni P (2005) The histone deacetylase inhibitor ITF2357 reduces production of proinflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 11:1-15
109. Linggi BE, Brandt SJ, Sun Z-W, Hiebert SW (2005) Translating the histone code into leukemia. J Cell Biochem 96:938-950
110. Liu T, Kuljaca S, Tee A, Marshall GM (2006) Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 32:157-165
111. LoRusso PM, Demchik L, Foster B, Knight J, Bissery M-C, Polin LM, Leopold WR III, Corbett TH (1996) Preclinical antitumor activity of CI-994. Invest New Drugs 14:349-356
112. Lu Q, Wang D-S, Chen C-S, Hu Y-D, Chen C-S (2005) Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem 48:5530-5535
113. Luong QT, O'Kelly J, Braunstein GD, Hershman JM, Koeffler HP (2006) Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res 12:5570-5577
114. Ma X, Fang Y, Beklemisheva AA, Dai W, Feng J, Ahmed T, Liu D, Chiao JW (2006) Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells. Int J Oncol 28:1287-1293
115. Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C, Keiser N, Santaniello F, Tomasi TB (2000) Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol 165:7017-7024
116. Mai A, Massa S, Pezzi R, Rotili D, Loidl P, Brosch G (2003) Discovery of (aryloxopropenyl)pyrrolyl hydroxamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A. J Med Chem 46:4826-4829
117. Mai A, Massa S, Rotili D, Simeoni S, Ragno R, Botta G, Nebbioso A, Miceli M, Altucci L, Brosch G (2006) Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors. J Med Chem 49:6046-6056
118. Maiso P, Carvajal-Vergara X, Ocio EM, López-Pérez R, Mateo G, Gutiérrez N, Atadja P, Pandiella A, San Miguel JF (2006) The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 66:5781-5789
119. Marks PA, Beslow R (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25:84-90
120. Marks PA, Richon VM, Miller T, Kelly WK (2004) Histone deacetylase inhibitors. Adv Cancer Res 91:137-168
121. Merck (2006) http://www.fda.gov/cder/Offices/OODP/whatsnew/vorinostat.htm
122. Mercuri E, Bertini E, Messina S, Solari A, D'Amico A, Angelozzi C, Battini R, Berardinelli A, Boffi P, Bruno C, Cini C, Colitto F, Kinali M, Minetti C, Mougini T, Morandi L, Neri G, Orcesi S, Pane M, Pelliccioni M, Pini A, Tiziano FD, Villanova M, Vita G, Brahe C (2007) Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology 68:51-55
123. Metzger J (2002) HDAC lightens a heavy heart. Nat Med 8:1078-1079
124. Miller AC, Whittaker T, Thibault A, Samid D (1999) Modulation of radiation response of human tumour cells by the differentiation inducers, phenylacetate and phenylbutyrate. Int J Radiat Biol 72:211-218
125. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev 6:38-51
126. Mishra N, Brown DR, Olorenshaw IM, Kammer GM (2001) Trichostatin A reverses skewed expression of CD154 interleukin-10, and interferon-g gene and protein expression in lupus T cells. Proc Natl Acad Sci USA 98:2628-2633
127. Monneret C (2005) Histone deacetylase inhibitors. Eur J Med Chem 40:1-13
128. Mora FD, Jones DK, Desai PV, Patny A, Avery MA, Feller DR, Smillie T, Zhou Y-D, Nagle DG (2006) Bioassay for the identification of natural product-based activators of peroxisome proliferator-activated receptor-g (PPAR g): the marine sponge metabolite psammaplin A activates PPAR g and induces apoptosis in human breast tumor cells. J Nat Prod 69:547-552
129. Moradei O, Maroun CR, Paquin I, Vaisburg A (2005) Histone deacetylase inhibitors: latest developments, trends and prospects. Curr Med Chem 5:529-560
130. Moreth K, Riester D, Hildmann C, Hempel R, Wegener D, Schober A, Schwienhorst A (2006) Active site tyrosine is essential for amidohydrolase but not for esterase activity of a class 2 histone deacetylase-like bacterial enzyme. Biochem J 401:659-665
131. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM (2001) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61:8492-8497
132. Munster PN, Marchion DC, Bicaku E, Schmitt ML, Padilla B, Stauffer P, Garrett C, Chiappori A, Sullivan DM, Daud AI (2006) Phase I trial of sequence-specific combination of the HDAC inhibitor, valproic acid (VPA), and the topoisomerase II inhibitor, epirubicin, in advanced solid tumors: clinical results and correlative studies. J Clin Oncol 24(18S):3068
133. Myzak MC, Karplus PA, Chung F-L, Dashwood RH (2004) A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res 64:5767-5774
134. Myzak MC, Dashwood WM, Orner GA, Ho E, Dashwood RH (2006) Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. FASEB J 20:506-508
135. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K, Pal A, Bornmann WG, Chiao PJ, Huang P, Xiong H, Abbruzzese JL, McConkey DJ (2006) Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 66:3773-3781
136. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F, Weisz A, de Lera AR, Gronemeyer H, Altucci L (2005) Tumor-selective action of HDAC inhibitors involves trail induction in acute myeloid leukemia cells. Nat Med 11:77-84
137. Nemunaitis JJ, Orr D, Eager R, Cunningham CC, Williams A, Mennel R, Grove W, Olson S (2003) Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer. Cancer J 9:58-66
138. Newmark HL, Young CW (1995) Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. J Cell Biochem 22(Suppl):247-253
139. Nielsen TK, Hildmann C, Riester D, Wegener D, Schwienhorst A, Ficner R (2006) Complex structure of a bacterial class 2 histone deacetylase homologue with a trifluoromethylketone inhibitor. Acta Crystallogr F (in press)
140. O'Connor OA (2006) Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma. Br J Cancer 95:S7-S12
141. O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, Zelenetz AD, Frankel S, Richon V, Marks P, Kelly WK (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24:166-173
142. Okada T, Tanaka K, Nakatani F, Sakimura R, Matsunobu T, Li X, Hanada M, Nakamura T, Oda Y, Tsuneyoshi M, Iwamoto Y (2006a) Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcome cells. Int J Cancer 118:90-97
143. Okada T, Uchibori R, Itawa-Okada M, Takahashi M, Nomoto T, Nonaka-Sarukawa M, Ito T, Liu Y, Mizukami H, Kume A, Kobayashi E, Ozawa K (2006b) A histone deacetylase inhibitor enhances recombinant adeno-associated virus-mediated gene expression in tumor cells. J Am Soc Gene Ther 13:738-746
144. Pauer LR, Olivares J, Cunningham C, Williams A, Grove A, Kraker A, Olson S, Nemunaitis J (2004) Phase I study of oral CI-994 in combination with
145. Peterson CL (2002) HDAC's at work: everyone doing their part. Mol Cell 9:921-929
146. Petri S, Kiaei M, Kipiani K, Chen J, Calingasan NY, Crow JP, Beal MF (2006) Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 22:40-49
147. Piacentini P, Donadelli M, Costanzo C, Moore PS, Palmieri M, Scarpa A (2006) Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch 448:797-804
148. Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR, Sachdev V, Fojo T, Bates SE (2006) Cardiac studies in patients treated with depsipeptide FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 12:3762-3773
149. Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, La Thangue NB, Brown R (2003) Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 3:721-728
150. Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HMW, Salumbides B, Sanni T, Atadja P, Pili R (2006a) Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 12:634-642
151. Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M, Lichenstein HS, Jeffers M (2006b) Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 5:2086-2095
152. Quaissi A, Quaissi M (2005) Molecular basis of Trypanosoma cruzi and Leishmania interaction with their host(s): exploitation of immune and defense mechanisms by the parasite leading to persistence and chronicity, features reminiscent of immune system evasion strategies in cancer diseases. Arch Immunol Ther Exp 53:102-114
153. Quaissi M, Quaissi A (2006) Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases. J Biomed Biotechnol 2006:1-10
154. Reddy P, Maeda Y, Hotary K, Liu C, Reznikov LL, Dinarello CA, Ferrara JLM (2004) Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 101:3921-3926
155. Remiszewski SW, Sambuccetti LC, Bair KW, Bontempo J, Cesarz D, Chandramouli N, Chen R, Cheung M, Cornell-Kennon S, Dean K, Diamantis G, France D, Green MA, Howell KL, Kashi R, Kwon P, Lassota P, Martin MS, Mou Y, Perez LB, Sharma S, Smith T, Sorensen E, Taplin F, Trogani N, Versace R, Walker H, Weltchek-Engler S, Wood A, Wu A, Atadja P (2003) N-hydroxy-3-phenyl-2- propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H- indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). J Med Chem 46:4609-4624
156. Richards DA, Boehm KA, Waterhouse DM, Wagener DJ, Krishnamurthi SS, Rosemurgy A, Grove W, Macdonald K, Gulyas S, Clark M, Dasse KD (2006) Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann Oncol 17:1096-1102
157. Riesland M, Brichta L, Hahnen E, Wirth B (2006) The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum Genet 120:101-110
158. Riester D, Wegener D, Hildmann C, Schwienhorst A (2004) Members of the histone deacetylase superfamily differ in substrate specificity towards small synthetic substrates. Biochem Biophys Res Com 324:1116-1123
159. Riester D, Hildmann C, Schwienhorst A, Meyer-Almes F-J (2007) Histone deacetylase inhibitor assay based on fluorescence resonance energy transfer. Anal Biochem 401:659-665
160. Riggs MG, Whittaker RG, Neumann JR, Ingram VM (1977) n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 268:462-464
161. Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, Boix-Chornet M, Caballero R, Alaminos M, Setien F, Paz MF, Herranz M, Palacios J, Arango D, Orntoft TF, Aaltonen LA, Schwartz SJ, Esteller M (2006) A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 38:566-569
162. Rosato RR, Grant S (2003) Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther 2:30-37
163. Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J, Sausville EA (2005) Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23:3912-3922
164. Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, Hoshino K, Quintas-Cardama A, Richon VM, Garcia-Manero G (2006) Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 108:1174-1182
165. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE (2002) Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8:718-728
166. Sankaranarayanapillai M, Tong WP, Maxwell DS, Pal A, Pang J, Bornmann WG, Gelovani JG, Ronen SM (2006) Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy. Mol Cancer Ther 5:1325-1334
167. Sato T, Suzuki M, Sato Y, Echigo S, Rikiishi H (2006) Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. Int J Oncol 28:1233-1241
168. Schröder CP, Maurer HR (2002) Tributyrin-induced differentiation promotes apoptosis of LS174T colon cancer cells in vitro. Int J Oncol 20:195-200
169. Shinji C, Maeda S, Imai K, Yoshida M, Hashimoto Y, Miyachi H (2006) Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors. Bioorg Med Chem 14:7625-7651
170. Simonini MV, Camargo LM, Dong E, Maloku E, Veldic M, Costa E, Guidotti A (2006) The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc Natl Acad Sci USA 103:1587-1592
171. Sonnemann J, Gange J, Pilz S, Stotzer C, Ohlinger R, Belau A, Lorenz G, Beck JF (2006a) Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. BMC Cancer 6:183
172. Sonnemann J, Kumar KS, Heesch S, Müller C, Hartwig C, Maass M, Bader P, Beck JF (2006b) Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int J Oncol 28:755-766
173. Stapnes C, Ryningen A, Gjertsen BT, Bruserud O (2006) Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused a persistent increase in peripheral blood platelet counts for a patient with acute myelogenous leukemia. Acta Oncol 45:346-349
174. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, Kazantsev A, Schmidt E, Zhu Y-Z, Greenwald M, Kirokawa R, Housman DE, Jackson GR, Marsh JL, Thompson LM (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413:739-743
175. Sutheesophon K, Kobayashi Y, Takatoku MA, Ozawa K, Kano Y, Ishii H, Furukawa Y (2006) Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemia cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib. Acta Haematol 115:78-90
176. Suzuki T, Miyata N (2005) Non-hydroxamate histone deacetylase inhibitors. Curr Med Chem 12:2867-2880
177. Suzuki T, Yokozaki H, Kuniyasu H, Hayashi K, Naka K, Ono S, Ishikawa T, Tahara E, Yasul W (2000) Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int J Cancer 88:992-997
178. Suzuki T, Kouketsu A, Itoh Y, Hisakawa S, MAeda S, Yoshida M, Nakagawa H, Miyata N (2006) Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. J Med Chem 49:4809-4812
179. Tabe Y, Konopleva M, Contractor R, Munsell M, Schober WD, Jin L, Tsutsumi-Ishi Y, Nagaoka I, Andreef M (2006) Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood 107:1546-1554
180. Tang R, Faussat A-M, Majdak P, Perrot J-Y, Chaoui D, Legrand O, Marie J-P (2004) Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 18:1246-1251
181. Ten Cate B, Samplonius DF, Bijma T, de Leij LFMH, Helfrich W, Bremer E (2007) The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemia cells. Leukemia 21:248-252
182. Vanniasinkam T, Ertl H, Tang Q (2006) Trichostatin-A enhances adaptive immune responses to DNA vaccination. J Clin Virol 36:292-297
183. Vega RB, Masuda K, Oh J, Barbosa AC, Yang X, Meadows E, McAnally J, Pomajzl C, Shelton JM, Richardson JA, Karsenty G, Olson EN (2004) Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119:555-566
184. Vigushin DM, Coombes RC (2002) Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 2:1-13
185. Wada CK, Frey RR, Curtin ML, Garland RB, Holms JH, Pease LJ, Guo J, Glaser KB, Marcotte PA, Richardson PL, Murphy SS, Bouska JJ, Tapang P, Magoc TJ, Albert DH, Davidsen SK, Michaelides MR (2003) Alpha-keto amides as inhibitors of histone deacetylase. Bioorg Med Chem Lett 13:3331-3335
186. Wade PA, Pruss D, Wolffe AP (1997) Histone acetylation: chromatin in action. Trends Biochem Sci 22:128-132
187. Wang D-F, Helquist P, Wiech NL, Wiest O (2005) Toward selective histone deacetylase inhibitor design: homology modeling docking studies, and molecular dynamics simulations of human class I histone deacetylases. J Med Chem 48:6936-6947
188. Warrell RP, He LZ, Richon V, Calleja E, Pandolfi PP (1998) Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90:1621-1625
189. Warren K, McCully CL, Dvinge H, Tjornelund J, Sehested M, Lichenstein HS, Balis FM (2006) http://www.curagen.com/uploaded_files/AACR20_3.PDF
190. Watanabe T, Hioki M, Fujiwara T, Nishizaki M, Kagawa S, Taki M, Kishimoto H, Endo Y, Urata Y, Tanaka N, Fujiwara T (2006) Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Exp Cell Res 312:256-265
191. Wegener D, Hildmann C, Schwienhorst A (2003a) Recent progress in the development of assays suited for histone deacetylase inhibitor screening. Mol Genet Metab 80:138-147
192. Wegener D, Wirsching F, Riester D, Schwienhorst A (2003b) A fluorogenic histone deacetylase assay well suited for high-throughput activity screening. Chem Biol 10:61-68
193. Weinmann H, Ottow E (2005) Histone deacetylase inhibitors: a survey of recent patents. Expert Opin Ther Pat 15:1677-1690
194. Weisberg E, Catley L, Kujawa J, Atadja P, Remiszewski S, Fuerst P, Cavazza C, Anderson K, Griffin JD (2004) Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. Leukemia 18:1951-1963
195. Witt O, Schweigerer L, Driever PH, Wolff J, Pekrun A (2004) Valproic acid treatment of glioblastoma multiforme in a child. Pediatr Blood Cancer 43:181
196. Xiao JJ, huang Y, Dai Z, Sadée W, Chen J, Liu S, Marcucci G, Byrd J, Covey JM, Wright J, Grever M, Chan KK (2005) Chemo-resistance to depsipeptide FK228 is mediated by reversible MDR1 induction in human cancer cell lines. J Pharmacol Exp Ther 314:467-475
197. Xu WS, Ngo L, Perez G, Dokmanovic M, Marks PA (2006) Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA 103:15540-15545
198. Yeow WS, Ziauddin MF, Maxhimer JB, Shamimi-Noori S, Baras A, Chua A, Schrump DS, Nguyen DM (2006) Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01. Br J Cancer 94:1436-1445
199. Yoo EJ, Lee BM (2005) Comparative mutagenicity of apicidin and apicidin derivatives (SD-0203 and SD-2007), histone deacetylase inhibitors. J Toxicol Environ Health A 68:2097-2109
200. Young DA, Lakey RL, Pennington CJ, Jones D, Kevorkian L, Edwards DR, Cawston TE, Clark IM (2005) Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Res Ther 7:R503-R512
201. Zalupski M, O'Shaughnessy JA, Vukelja SJ, Shields A, Diener K, Grove W (2000) Phase II trial of CI-994 in patients (pts) with advanced pancreatic cancer (APC). Proc Annu Meet Am Soc Clin Oncol 19:285a, (Abstract 1115)
202. Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y, Mita K, Hamaguchi M, Hayashi S-I, Iwase H (2004) HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 10:6962-6968
203. Zhang C, Richon V, Ni X, Talpur R, Duvic M (2005) Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 125:1045-1052
204. Zhang X, Yashiro M, Ren J, Hirakawa K (2006) Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol Rep 16:563-568